Mauled by a major setback, Incyte is pointing to a better future — but concedes it also had to scrap another failed study
At least Incyte $INCY has Jakafi.
With the biotech’s IDO1 pipeline effort foundering on bad data, Incyte today led off the annual update on its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
